Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease

Wellens J.Edmans M.Obolski U.McGregor C.G.C.Simmonds P.Turner M.Jarvis L.Skelly D.Dunachie S.Barnes E.Eyre D.W.Colombel J.F.Wong S.Y.Klenerman P.Lindsay J.O.Satsangi J.Thompson C.P.Mahidol University2023-06-182023-06-182022-09-01Gut Vol.71 No.9 (2022) , 1919-1922https://repository.li.mahidol.ac.th/handle/20.500.14594/85602MedicineCombination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel diseaseLetterSCOPUS10.1136/gutjnl-2021-3263122-s2.0-851338452651468328834911744